ESTRO 2025 - Abstract Book

S1332

Clinical - Lung

ESTRO 2025

Conclusion: These results confirmed the safety and efficacy of SBRT in SPN in a long-term FUP cohort. The absence of any clinically significant differences in patterns of tumor recurrence between the two groups, supports the validity of SBRT, even without histological confirmation. The role of a thorough use of radiologic/metabolic criteria of non histologically confirmed SPN, remains pivotal.

Keywords: Lung SBRT, ES-NSCLC, Solitary Pulmonary Nodule

References: 1. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College 2. Field JK, Smith RA, Aberle DR, et al. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol 2012;7:10-9. 3. Lee P, Loo BW Jr, Biswas T, et al. Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Int J RadiatOncolBiolPhys. 2021;110(1):160-171.

1705

Digital Poster CT-based radiomics for predicting response to chemoradiation in locally advanced lung adenocarcinoma Erika Z Chung 1 , Laurentius O Osapoetra 1 , Shopnil Prasla 1 , Patrick Cheung 2,3 , Ian Poon 2,3 , Ines Menjak 4,5 , Gregory Czarnota 2,6,1 1 Physical Sciences, Sunnybrook Research Institute, Toronto, Canada. 2 Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada. 3 Radiation Oncology, University of Toronto Health Sciences Centre, Toronto, Canada. 4 Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada. 5 Medical Oncology, University of Toronto, Toronto, Canada. 6 Radiation Oncology, University of Toronto, Toronto, Canada Purpose/Objective: The standard treatment for patients with locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiation. However, clinical responses are heterogeneous and generally not known until after completion of therapy. Multiple studies have investigated imaging predictors (radiomics) for different types of cancer histologies,